title: Chemotherapy with tauromustine in advanced non-small cell lung cancer. A trial of the Phase II Study Group of the Association for Medical Oncology of the German Cancer Society.
abstract: Tauromustine (TCNU) is a newly developed nitrosourea compound. As a result of molecular modification, TCNU is more hydrophilic than BCNU and CCNU. In experimental data there was a high therapeutic index, especially in Walker 256 carcinosarcoma in rats, and in phase I trials antitumor activity was observed in NSCLC (10/33 remissions). There was also activity in melanoma, breast cancer, pleuramesotheliomas and ovarian cancer. To determine the effectiveness, duration of response and toxicity of TCNU the following phase II trial was performed. Patients received 130 mg/m2 TCNU every 35 days orally. Twenty-five patients were treated; 22 were evaluable. The female/male ratio was 18/4, 1 patient was stage III, 21 patients stage IV, the mean age was 62.3 years (range 32-70). Between 1 and 4 courses (mean 1.9) were administered. Histology was as follows: 6 squamous cell, 11 adenocarcinoma, 2 large cell and 3 polymorph cell carcinomas. No objective response (CR + PR) was observed; 6/18 patients had stable disease, 7/18 progression and 5/18 early progression. The median survival time is 4.9 months. The most severe side effect was thrombocytopenia (WHO grade 3 + 4, 4/22 patients). TCNU administered at this dose and schedule does not show substantial antitumor activity in patients with NSCLC. The fact that no objective tumor remission was observed suggests that the true response rate is less than 20% (p less than 0.05). It is improbable that TCNU has a relevant impact on the course of inoperable NSCLC.
authors.affiliation: Department of Thoracic Oncology, Grosshansdorf Hospital.
authors.forename: U
authors.initials: U
authors.lastname: Gatzemeier
authors.forename: P
authors.initials: P
authors.lastname: Drings
authors.forename: L
authors.initials: L
authors.lastname: Edler
authors.forename: H H
authors.initials: HH
authors.lastname: Fiebig
authors.forename: A
authors.initials: A
authors.lastname: Hinke
authors.forename: K
authors.initials: K
authors.lastname: Rieche
authors.forename: H W
authors.initials: HW
authors.lastname: Tessen
mesh_terms: D000970:Antineoplastic Agents; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D004341:Drug Evaluation; D005500:Follow-Up Studies; D005860:Germany, West; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015337:Multicenter Studies as Topic; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D013654:Taurine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D013654:Taurine; C052991:1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea